Janneke van der Kamp
About Janneke van der Kamp
Independent non-executive director at NewAmsterdam Pharma Company N.V. since April 2023; age 50; current term expires in 2026 . CEO of Norgine; previously Chief Commercial Officer at Grünenthal and two decades at Novartis including Global Head of Product & Portfolio Strategy (2016–2018) and Head of Pharma Region Europe (2019–2022); M.S. in Chemistry (Utrecht University) and MBA (INSEAD) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Novartis | Global Head of Product & Portfolio Strategy | 2016–2018 | Supported launches in cardiovascular; work across immunology, dermatology, neuroscience, ophthalmology, respiratory |
| Novartis | Head of Pharma Region Europe | 2019–2022 | Regional leadership across Europe |
| Grünenthal | Chief Commercial Officer | Not disclosed | Commercial leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Norgine | Chief Executive Officer | Current | Pharma operator experience |
Board Governance
- Independence: Board determined Janneke is independent under Nasdaq Rule 5605(a)(2) (all directors except Davidson, Kastelein, Topper are independent) .
- Attendance: Board met four times in 2024; no director attended fewer than 75% of Board or committee meetings .
- Committee assignment: Member, Nomination & Corporate Governance Committee (Chair: William H. Lewis) .
| Governance Item | Detail |
|---|---|
| Board Tier | Single-tier: 1 executive, 10 non-executives |
| Independence | Independent director |
| Board Meetings in 2024 | 4 meetings; ≥75% attendance |
| Committees | Nomination & Corporate Governance (member) |
| Committee Chairs | Audit: John W. Smither; Compensation: Louis Lange; Nominating & CG: William H. Lewis |
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Retainer (cash) | $43,000 | Standard for non-employee directors |
| Committee Fees (cash) | $5,000–$20,000 | Chair/member fees vary by committee |
| 2024 Cash Fees Earned (J. van der Kamp) | $46,375 | Fees earned/pd in cash in 2024 |
Performance Compensation
| Component | Grant Date | Units/Value | Vesting/Terms |
|---|---|---|---|
| Option Awards (2024 earned value) | Not disclosed | $51,417 (grant-date fair value) | Company grants options to non-employee directors; details not individually disclosed |
| Options Outstanding (as of 12/31/2024) | — | 28,000 options | Option awards outstanding (count) |
Company practices emphasize equity (stock options) for long-term alignment; options generally have 10-year terms and time-based vesting in NEO program, while director award specifics are not separately disclosed .
Other Directorships & Interlocks
| Company | Role | Public/Private | Potential Interlock/Conflict |
|---|---|---|---|
| Norgine | CEO | Not disclosed | No related-party transactions disclosed with NAMS; director independence affirmed; Company policy requires recusal for conflicts |
Expertise & Qualifications
- Deep pharma commercial and portfolio strategy expertise across EU and global roles; led launches in cardiovascular and other therapeutic areas .
- Technical education (Chemistry M.S.) and MBA; seasoned operator now leading Norgine .
Equity Ownership
| Holder | Total Beneficial Ownership | % Outstanding | Breakdown | Pledging/Hedging |
|---|---|---|---|---|
| Janneke van der Kamp | 13,295 shares (via options exercisable within 60 days) | <1% | Exercisable options within 60 days: 13,295 ; Total options outstanding: 28,000 | No pledging by directors disclosed; hedging/pledging prohibited by policy |
Governance Assessment
- Board effectiveness: Independent status, active on Nomination & Corporate Governance, and ≥75% attendance support investor confidence in oversight rigor .
- Compensation alignment: Modest cash retainer with equity options fosters long-term alignment; 2024 cash fees $46,375 and option value $51,417 indicate balanced cash/equity mix for directors .
- Conflicts/related-party: No related-party transactions disclosed involving Janneke; the Company enforces conflict policies (directors recuse when conflicts arise) and prohibits hedging/pledging, mitigating misalignment risks .
- RED FLAGS: None disclosed specific to Janneke; note concurrent external CEO role could pose potential conflicts only if transactional ties emerge, but none are disclosed; independence affirmed .